Prior studies have revealed that treatment utilizing cytoreductive surgery to remove all visible tumor in combination with intraoperative or perioperative high-dose regional chemotherapy to kill any remaining tumor cells offers the best prognosis and has become the standard of care in treating peritoneal mesothelioma.
In an effort to identify the factors that contribute to long term survival, an analysis of 211 cases of peritoneal mesothelioma from 1992 and 2010 was performed by doctors at the University of Maryland School of Medicine.
Patients treated with cytoreductive surgery and hyperthermic intraoperative peritoneal chemotherapy showed median survival of 38.4 months, with 41% surviving at least 5 years, and 26% surviving to 10 years. The use of the chemotherapy agent Cisplatin resulted in prolonged survival in all patient groups over the use of mitomycin-C which in the past was the most common agent used.
Women tended to respond better to the treatment than men. Age and completeness of resection or tumor removal also contributed to the most favorable response. Ultimately, the stage of the disease played a key role in patients’ response to treatment.
Peritoneal mesothelioma tends to offer a better prognosis than pleural mesothelioma due to the location of the disease which is surgically more accessible, but if left untreated is just as aggressive as pleural mesothelioma. Patients exhibiting the longest survival rate had regular post treatment follow-up and additional treatment at the onset
of any recurrence of the disease.
Read the full abstract here.
Peritoneal patient profiles:
- Tammy Jordan - 13 Year Survivor
- Michael Winkelman - 11 Year Survivor
- Paul Zygielbaum - 10 Year Survivor
- Sue Huff - 7 Year Survivor
- Tom Bradford - 5 Year Survivor